The price of Esperion Therapeutics Inc. (NASDAQ:ESPR) shares last traded on Wall Street fell -2.37% to $6.18.
Based on available information, 11 analysts follow Esperion Therapeutics Inc. (NASDAQ:ESPR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $3.00, we find $9.00. Given the previous closing price of $6.33, this indicates a potential upside of 42.18 percent. ESPR stock price is now -17.92% away from the 50-day moving average and -2.87% away from the 200-day moving average. The market capitalization of the company currently stands at $427.66M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 3 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $11.27 as their price target over the next twelve months.
With the price target reduced from $7 to $6, Credit Suisse Downgraded its rating from Neutral to Underperform for Esperion Therapeutics Inc. (NASDAQ: ESPR). On May 05, 2022, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $6, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, Foody Joanne M., Chief Medical Officer sold 942 shares of the company’s stock on Oct 18. The stock was sold for $7,242 at an average price of $7.69. Upon completion of the transaction, the Chief Medical Officer now directly owns 108,135 shares in the company, valued at $0.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 18, Chief Commercial Officer Warren Eric sold 107 shares of the business’s stock. A total of $823 was realized by selling the stock at an average price of $7.69. This leaves the insider owning 53,662 shares of the company worth $0.33 million. Insiders disposed of 14,804 shares of company stock worth roughly $91488.72 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ESPR stock. A new stake in Esperion Therapeutics Inc. shares was purchased by J. GOLDMAN & CO LP during the first quarter worth $3,418,000. TANG CAPITAL MANAGEMENT LLC invested $3,090,000 in shares of ESPR during the first quarter. In the first quarter, COMMODORE CAPITAL LP acquired a new stake in Esperion Therapeutics Inc. valued at approximately $2,889,000. SILVERARC CAPITAL MANAGEMENT, LLC acquired a new stake in ESPR for approximately $1,941,000. PARKMAN HEALTHCARE PARTNERS LLC purchased a new stake in ESPR valued at around $1,832,000 in the second quarter. In total, there are 188 active investors with 87.80% ownership of the company’s stock.
A candlestick chart of Esperion Therapeutics Inc. (NASDAQ: ESPR) showed a price of $6.26 on Thursday morning. During the past 12 months, Esperion Therapeutics Inc. has had a low of $3.28 and a high of $8.87. The fifty day moving average price for ESPR is $7.53 and a two-hundred day moving average price translates $6.36 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.05, missing analysts’ expectations of -$0.93 by -0.12. This compares to -$2.62 EPS in the same period last year. The company reported revenue of $18.98 million for the quarter, compared to $14.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 31.72 percent. For the current quarter, analysts expect ESPR to generate $19.91M in revenue.
Esperion Therapeutics Inc.(ESPR) Company Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
